OM:QLINEA

Stock Analysis Report

Executive Summary

Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.

Share Price & News

How has Q-linea's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.9%

QLINEA

5.5%

SE Medical Equipment

2.1%

SE Market


1 Year Return

n/a

QLINEA

34.0%

SE Medical Equipment

12.1%

SE Market

Return vs Industry: Insufficient data to determine how QLINEA performed against the Swedish Medical Equipment industry.

Return vs Market: Insufficient data to determine how QLINEA performed against the Swedish Market.


Shareholder returns

QLINEAIndustryMarket
7 Day-2.9%5.5%2.1%
30 Day0.8%1.3%1.6%
90 Day3.9%1.6%3.7%
1 Yearn/a35.4%34.0%16.8%12.1%
3 Yearn/a54.9%36.6%32.2%12.4%
5 Yearn/a72.9%44.6%62.8%28.3%

Price Volatility Vs. Market

How volatile is Q-linea's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Q-linea undervalued compared to its fair value and its price relative to the market?

3.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QLINEA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QLINEA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QLINEA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: QLINEA is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QLINEA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QLINEA is good value based on its PB Ratio (3.5x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Q-linea forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

18.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QLINEA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QLINEA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QLINEA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QLINEA's revenue (60.2% per year) is forecast to grow faster than the Swedish market (4.5% per year).

High Growth Revenue: QLINEA's revenue (60.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QLINEA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Q-linea performed over the past 5 years?

-54.7%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: QLINEA is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare QLINEA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QLINEA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: QLINEA has a negative Return on Equity (-34.3%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: QLINEA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: QLINEA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Q-linea's financial position?


Financial Position Analysis

Short Term Liabilities: QLINEA's short term assets (SEK289.1M) exceeds its short term liabilities (SEK24.9M)

Long Term Liabilities: QLINEA's short term assets (289.1M) exceeds its long term liabilities (499.0K)


Debt to Equity History and Analysis

Debt Level: QLINEA's debt to equity ratio (0.2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if QLINEA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: QLINEA has a low level of unsold assets or inventory.

Debt Coverage by Assets: QLINEA's debt is covered by short term assets (assets are 314.599560x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QLINEA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: QLINEA has sufficient cash runway for 1.458697 years if free cash flow continues to reduce at historical rates of -39% each year.


Next Steps

Dividend

What is Q-linea's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.6%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate QLINEA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate QLINEA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if QLINEA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QLINEA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QLINEA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Q-linea's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Jonas Jarvius (48yo)

11.8yrs

Tenure

kr1,339,000

Compensation

Dr. Jonas Jarvius, Ph.D serves as the Chief Executive Officer and President of Q-linea AB. Dr. Jarvius serves as part time scientist at Rudbeck Laboratory Uppsala University. Dr. Jarvius Co-founded Olink A ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jonas's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Jonas's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.3yrs

Average Tenure

55yo

Average Age

Experienced Management: QLINEA's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

1.8yrs

Average Tenure

65yo

Average Age

Experienced Board: QLINEA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jonas Jarvius (48yo)

    CEO & President

    • Tenure: 11.8yrs
    • Compensation: kr1.34m
  • Anders Lundin (55yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
  • Nils Kristensen (56yo)

    Chief Operating Officer

    • Tenure: 2.8yrs
  • Charlotta Göransson (47yo)

    Marketing Director

    • Tenure: 2.8yrs
  • Tiziana Di Martino

    Chief Medical Officer

    • Tenure: 0.3yrs
  • Thomas Fritz (55yo)

    Chief Commercial Officer

    • Tenure: 0.08yrs

Board Members

  • Marcus Storch (77yo)

    Director

    • Tenure: 0yrs
  • Hans Johansson (65yo)

    Director

    • Tenure: 1.8yrs
  • Per-Olof Wallström (70yo)

    Director

    • Tenure: 0yrs
  • Ulf Landegren (67yo)

    Director

    • Tenure: 7.8yrs
  • Marianne Hansson (56yo)

    Director

    • Tenure: 1.8yrs
  • Mats Nilsson (50yo)

    Director

    • Tenure: 11.8yrs
  • Erika Eriksson (57yo)

    Chairperson

    • Tenure: 1.8yrs

Company Information

Q-linea AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Q-linea AB (publ)
  • Ticker: QLINEA
  • Exchange: OM
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.520b
  • Shares outstanding: 23.02m
  • Website: https://www.qlinea.com

Number of Employees


Location

  • Q-linea AB (publ)
  • Dag Hammarskjölds väg 52 A
  • Uppsala
  • Uppsala County
  • 752 37
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QLINEAOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKDec 2018
3F8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2018
QLINESBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBSEKDec 2018

Biography

Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. It offers inventive systems for in vitro diagnostics for infectious diseases. The comp ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:54
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.